The adverse effect profile of carvedilol is similar to that of other alpha- and beta-blockers. From clinical trials, the most frequently reported adverse events are headache (8%) and dizziness (7%), as well as tiredness and weakness (4%) . These effects tend to be more pronounced in the elderly and in patients with more severe heart failure (NYHA classes III and IV) . The incidence of orthostatic hypotension is higher than that seen with other beta-blockers but comparable with that seen with alpha-blockers. Dizziness and orthostatic hypotension can be reduced by gradual dose titration and administration with food. Other side effects common to beta-blockers, such as bradycardia, dyspnea and insomnia, have also been reported.
Short term trials in hypertensive patients with noninsulin-dependent have demonstrated that carvedilol does not appear to interfere with glycemic control, as measured by both fasting and postprandial blood glucose levels, as well as glycosylated hemoglobin . A one-year follow-up of lipid levels in an open-label hypertension trial demonstrated no changes in serum triglycerides, total cholesterol, high density lipoprotein or LDL levels.